Funding profile · Dialysis vascular access

VenoStent

Six Form D notices since 2018, $29.2 million sold, $7.4 million of federal awards, and a $10 million debt round in April 2026 that no press release mentions.

$29.2MSold across six Form D notices, 2018 to 2026
$10.0MApril 2026 debt and options offering, fully subscribed
$7.43MNIH and NSF awards on record, about a fifth of the total
$20.0MSeries A as announced in June 2024, company-reported

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Mar 2018 Debt with options $70,000 of $400,000 4 Form D
Jun 2019 Equity $263,929 of $300,000 8 Form D
May 2020 Options to acquire $515,000 of $535,000 16 Form D
Jan 2021 Seed, equity $2,242,619 of $3,000,000; $2.3M announced 24 · Creative Ventures led, with IAG Capital Partners, C3 Ventures, Olima Ventures, Texas Halo Fund, Cowtown Angels, SP Investment Fund Form D and release
Jul 2023 Series A, first close $16,062,824 of $21,182,882; $16M announced 60 · Good Growth Capital and IAG Capital Partners co-led, with TMC Venture Fund, SNR, Baylor Angel Network, Creative Ventures, Cowtown Angels, Alumni Ventures Form D and release
Jun 2024 Series A, final close $4M added, round called $20M Norwest Venture Partners Company release
Apr 2026 Debt with options $10,000,000 of $10,000,000 29 · not named Form D
2018 to 2026 Federal awards $7,427,151 NSF STTR and SBIR; NIH NHLBI; KidneyX prize NSF, NIH

What the filings show

VenoStent, Inc. · Form D · filed May 1, 2026

First sale
Apr 10, 2026
Offered
$10,000,000 debt with options to acquire
Sold
$10,000,000 · $0 remaining
Investors
29 · average about $344,828 · $10,000 minimum
Exemption
Rule 506(b)
Related persons
Timothy Boire, Geoffrey Lucks (officers, directors); Robert Crutchfield, Joel Whitley, Jim Monsor (directors)
Filing
SEC EDGAR, CIK 0001734734

VenoStent, Inc. · Form D · filed Jul 19, 2023

First sale
Jul 5, 2023
Offered
$21,182,882 equity
Sold
$16,062,824 · $5,120,058 remaining
Investors
60 · average about $267,714
Exemption
Rule 506(b)
Related persons
Boire, Lucks (officers, directors); Crutchfield, Whitley, Monsor (directors)
Filing
SEC EDGAR, CIK 0001734734

VenoStent, Inc. · Form D · filed Feb 16, 2021

First sale
Jan 29, 2021
Sold
$2,242,619 equity of $3,000,000 · $757,381 remaining
Investors
24 · average about $93,442
Related persons
Boire, Lucks (officers, directors); Kulika Weizman (director)
Address
Nashville, TN · Delaware, incorporated 2017

VenoStent, Inc. · Form D · filed Jun 10, 2020

Sold
$515,000 of $535,000, options to acquire · first sale May 26, 2020
Investors
16 · average about $32,188

VenoStent, Inc. · Form D · filed Jul 10, 2019

Sold
$263,929 equity of $300,000 · first sale Jun 25, 2019
Investors
8 · average about $32,991 · $9,999 minimum

VenoStent, Inc. · Form D · filed Mar 22, 2018

Sold
$70,000 of $400,000, debt with options · first sale Mar 7, 2018
Investors
4 · $330,000 left unsold

Reading the filings

  1. The Series A was one offering, filed once.July 2023 reported $16,062,824 sold against a $21,182,882 offering, leaving $5,120,058 open. Eleven months later the company announced $4,000,000 from Norwest that rounded the round out at $20 million. $16,062,824 plus $4,000,000 is $20,062,824, and no new Form D followed. The second close fit inside room the first filing had already reserved.
  2. The 2026 round is debt, and nobody announced it.May 1, 2026 reports $10,000,000 sold of $10,000,000 offered, in debt plus options to acquire, from 29 investors, an average of about $344,828 against a $10,000 minimum. First sale was April 10, 2026 and the filing landed 21 days later, where Form D is due within 15. Notes at that minimum across 29 holders read as a bridge drawing on existing and individual backers, not a priced round led by a fund.
  3. The board follows the money.February 2021 lists Boire, Lucks and Kulika Weizman, then a principal at Creative Ventures, which led that seed. The 2023 and 2026 notices drop Weizman and add Robert Crutchfield, Joel Whitley and Jim Monsor. Crutchfield is an operating partner at Good Growth Capital and Whitley a partner at IAG Capital Partners, the two firms that co-led the Series A. Norwest’s Zack Scott and Ehi Akhirome were announced in June 2024 as board observers and appear nowhere in 2026, which is what an observer seat looks like.
  4. A fifth of the capital is non-dilutive.$7,427,151 of NIH and NSF awards against $29,154,372 of Form D sales. The $3.6 million NIH grant announced in June 2024 matches the R44 portion of project HL151025, which shows $1,212,392 in each of fiscal 2024, 2025 and 2026, or $3,637,176. Three further awards worth $1,921,359 began in September 2026, two for manufacturing scale up and long term degradation testing.
  5. Grants carried the first five years, from Nashville.Across the 2018 to 2021 notices the company offered $4,235,000 and sold $3,091,548, about 73 percent, in average checks running from $17,500 to $93,442. Federal awards over that window were larger. Those four notices give a Nashville, Tennessee address; 2023 and 2026 give Houston, Texas. Delaware incorporation stays constant. Venture money arrived only after the feasibility data did.

Commercial signals

Signal Detail Source type
Regulatory No FDA clearance or approval. Breakthrough designation May 2022, IDE May 2023. SelfWrap is labeled for investigational use and is not for sale in any country. Public record
Revenue None disclosed. Every Form D marks the revenue range “Decline to Disclose.” Public record
Clinical SAVE-FistulaS, 600 estimated, 28 sites recruiting, primary completion estimated June 2027. Public record
Evidence Feasibility results presented at the VEITHsymposium in November 2024. No peer-reviewed publication found. Not found
Headcount 17, per the company’s Y Combinator page. Company-stated
Timing An investor note said the company expected FDA approval in late 2026. The trial is still recruiting. Overtaken

What to watch

  • A priced round converting the April 2026 notes, and the Form D with it.
  • Whether a Series B arrives before the pivotal trial reads out, or after.
  • The June 2027 primary completion date, which has already outlived a projected 2026 approval.
  • A premarket approval submission, the pathway the founders describe choosing.

The VenoStent story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Qventus: Shared investor: M Norwest Venture Partners. Software that automates the logistics wrapped around care: who gets the operating room, when a patient goes home, which fax gets read
  • Allotrope Medical: Shared investor: Texas Halo Fund. A Houston surgical resident built a box that makes the ureter move on command, cleared it in 2020, and sold the company in 2023
  • Trestle Biotherapeutics: Shared investor: C3 Ventures. A San Diego company building implantable, stem cell derived kidney tissue on biofabrication science licensed from Harvard
  • CellChorus: Shared investor: Texas Halo Fund. A University of Houston spinout that films immune cells one at a time and scores how well each one kills

Sources

  1. Public recordSix Form D filings, VenoStent, Inc., CIK 0001734734SEC EDGAR · Mar 2018 to May 2026
  2. Public recordNIH RePORTER, eight NHLBI awardsNIH · FY2020 to FY2026
  3. Public recordNSF awards 1819996 and 1927086NSF · 2018 to 2023
  4. Public recordClinicalTrials.gov NCT06001827 and NCT05418816ClinicalTrials.gov · updated Feb 17, 2026
  5. Public recordFDA 510(k) and PMA databasesFDA · searched Sep 22, 2026
  6. CompanySeries A and IDE releases, 2021, 2023 and 2024PR Newswire and ACCESSWIRE
  7. IndependentVenoStent raises $20M for bioabsorbable perivascular wrapMassDevice · Jun 27, 2024
  8. IndependentHouston health tech startup secures $20M series A, NIH grantInnovationMap · Jul 3, 2024
  9. InvestorVenoStent: The Promise of Safer Treatment for Dialysis PatientsNorwest Venture Partners · accessed Sep 22, 2026

Compiled from SEC, NIH, NSF, FDA and ClinicalTrials.gov public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in VenoStent. This page is not an offer to sell or a recommendation to buy any security.